AstraZeneca signs US$5 billion research deal with China's CSPC
A general view of AstraZeneca offices and the corporate logo in Cambridge, England, on July 18, 2020. (AP Photo/Alastair Grant)
AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday.
The deal marks the latest effort by AstraZeneca to revive its business in China, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports.
Under the agreement, the two companies will collaborate to discover and develop pre-clinical candidates for potential treatments targeting chronic diseases, with CSPC conducting AI-driven research in Shijiazhuang City.
Cambridge, U.K.-based AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion in development milestones and $3.6 billion in sales-related milestones, AstraZeneca said.
In March, AstraZeneca announced plans to invest $2.5 billion in a research and development hub in Beijing, as it works to rebuild trust in its second-largest market.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Tasim Zahid, Reuters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 hours ago
- Globe and Mail
BioGrowing Shines at Probiota Americas 2025, Leading Innovation in Probiotic Applications for Oral and Weight Management
VANCOUVER - June 13, 2025 - BioGrowing, the Diamond Sponsor of Probiota Americas 2025, showcased groundbreaking advancements in oral health and weight management at the event. Through keynote presentations and panel discussions, the Chinese probiotic leader demonstrated its cutting-edge capabilities to the global scientific community. Innovative Oral Probiotic Solution Targets Billion-Dollar Market Dr. Zhanxi Hao, Vice President of the BioGrowing Research Institute, delivered a inspiring speech titled "Innovations In Oral Probiotics Research And Market Trends." He highlighted the rapid growth of the global oral healthcare market, projected to exceed $700 billion USD by 2030, with China's oral probiotic segment showing equally strong momentum. Probiotics, as core modulators of the oral microbiome, are driving oral health products to become a major market force due to their proven efficacy. As a pioneer in China's probiotic industry, BioGrowing has achieved technological leadership in oral probiotics through years of strain development: Lacticaseibacillus paracasei LPc-G110: The clinical research validating these oral probiotic strains was conducted at the Academic Centre for Dentistry Amsterdam (ACTA), ranked No. 1 in Europe and No. 2 globally in the QS World University Rankings for Dentistry. The trials demonstrated that BioGrowing's oral probiotic formulations effectively: Improve gingivitis, Reduce dental plaque formation, Decrease levels of harmful oral bacteria, Enhance oral micro-ecological stability. Ligilactobacillus salivarius LS-G60: Addresses halitosis at its source by inhibiting volatile sulfur compound (VSC) production. Clinically proven to outperform conventional treatments in combating halitosis. The Flora-Focus® Oral Health Fomula , developed based on these innovations, is now in industrial application. Concurrently launched, the novel OralBubble™ Probiotic Microbubble Lozenges deliver 10 Billion CFU per piece of clinically validated strains, offering a one-stop solution for 8 major oral concerns and meeting on-the-go oral health needs. Finished product testing confirms that the probiotic bubble tablets achieve VSC (volatile sulfur compound) inhibition rates of 98.76% at 16 hours and 98.09% at 24 hours post-administration, clinically validating their efficacy in delivering 24-hour oral freshness and halitosis reduction. Triple-Strain Consortium Addresses Global Obesity Challenge During the "Probiotics And Weight Management: Science or Myth?" roundtable discussion, BioGrowing's experts presented the company's latest research findings and scientific evidence supporting probiotic efficacy in weight management, exploring practical applications and potential in this field. Highlighting the public health crisis – global obesity rates surged from 36% (2000) towards 50% (2023) per the World Obesity Atlas 2025, with China designating 2025 as its "Weight Management Year" – BioGrowing introduced the Flora-Focus® Weight Management Fomula: Features a targeted triple-strain consortium: Lactobacillus gasseri LG-G12, Lactiplantibacillus plantarum ZJUF T17, and Lactiplantibacillus plantarum ZJUF T34. Mechanism: Enhances lipid metabolism efficiency, increases beige adipose tissue content, and inhibits high-fat diet-induced weight gain, while reducing hyperlipidemia risks associated with obesity. Provides a precise weight management solution for individuals with frequent dietary indiscretions, weight management goals, or dyslipidemia. Expanding Health Frontiers Through Scientific Rigor "From oral microbiome modulation to metabolic management, we are systematically building comprehensive probiotic health solutions," emphasized Dr. Hao. BioGrowing's relevant products have already secured international orders, marking the global reach of China's microbial technology innovation. Moving forward, BioGrowing remains committed to expanding health frontiers, delivering science-backed, safe, and effective health solutions to consumers worldwide. Media Contact Company Name: BIOGROWING CO.,LTD. Contact Person: Echo Sun Email: Send Email Country: China Website:
Globe and Mail
11 hours ago
- Globe and Mail
AMD Stock Trades Higher Than Industry at 5.63X P/S: Hold or Fold?
Advanced Micro Devices AMD shares are currently overvalued, as suggested by its Value Score of D. The stock is trading at a premium, with a forward 12-month Price/Sales of 5.63X compared with the industry's 3.60X. Price/Sales (F12M) AMD shares have lost 3.9% in the year-to-date period, underperforming the Zacks Computer and Technology sector's increase of 2.5% and the Zacks Computer – Integrated Systems industry's growth of 16.4%. The underperformance can be attributed to increasing macroeconomic challenges and uncertainty, which are attributed to higher tariffs. Export controls on certain Instinct GPUs to China posed a regulatory challenge. AMD Stock Performance However, AMD is benefiting from its expanding portfolio, accretive acquisitions and rich partner base. AMD Expands AI Reach With New MI350 GPUs and Key Partners AMD is strengthening its footprint in the artificial intelligence (AI) market through an expanding portfolio. AMD recently introduced its comprehensive, end-to-end AI platform at the 2025 Advancing AI event, introducing the powerful Instinct MI350 Series GPUs with 4x generational AI compute gains. The company also showcased its open, rack-scale AI infrastructure and ROCm 7 software stack, enabling scalable, energy-efficient AI deployment. Strategic partners like Meta Platforms META, OpenAI, Microsoft MSFT, and Oracle ORCL highlighted AMD's growing role in powering next-gen AI workloads. Meta Platforms announced the broad deployment of AMD Instinct MI300X for Llama 3 and Llama 4 inference. Meta Platforms also expressed strong interest in the MI350 Series and is collaborating with AMD on future AI roadmaps, including the MI400 platform. Microsoft also announced that AMD Instinct MI300X is powering both proprietary and open-source models in production on Microsoft Azure. The collaboration with Microsoft supports scalable AI workloads across the cloud. Oracle Cloud Infrastructure is among the first to adopt AMD's open rack-scale AI infrastructure featuring the MI355X GPUs. Oracle is also building zettascale AI clusters using up to 131,072 MI355X GPUs to support large-scale AI workloads. AMD Benefits From Expanding EPYC Portfolio AMD's expanding EPYC portfolio has been noteworthy. The company's strong adoption of fifth-gen EPYC Turin processors and expanding Instinct AI accelerator deployments across hyperscalers and enterprises have also been major growth drivers for its success. EPYC processors are now deployed by all top 10 telecom, aerospace, and semiconductor companies. These processors are also gaining momentum in automotive, manufacturing, and energy sectors. Building on this momentum, the company recently announced that Nokia has adopted its fifth-gen EPYC 9005 Series processors for the Nokia Cloud Platform. These processors will enhance performance per watt for containerized workloads, which are important to 5G Core, edge, and enterprise applications. This integration supports telecom networks in meeting rising data demands while improving energy efficiency and reducing environmental impact. AMD is also benefiting from accretive acquisitions to strengthen its AI ecosystem and bridge the technological gap with NVIDIA in the race for AI dominance. Exiting first-quarter 2025, AMD completed its acquisition of ZT Systems, combining its leadership in systems and racks with AMD's powerful GPUs, CPUs, networking silicon, and open-source software to tap into the $500 billion data center AI accelerator market by 2028. AMD's Q2 Guidance Unimpressive Despite an expanding portfolio and a rich partner base, AMD is expected to be hurt by export restrictions on GPUs to China, which will be a headwind and stiff competition from NVIDIA. AMD expects second-quarter 2025 revenues of $7.4 billion (+/-$300 million). At the mid-point of the revenue range, this represents year-over-year growth of approximately 27%. AMD expects approximately a $700 million reduction in second-quarter 2025 revenues due to halted MI308X shipments to China. AMD's Earnings Estimates Trend Downward The Zacks Consensus Estimate for AMD's second-quarter 2025 earnings is currently pegged at 56 cents per share, which has decreased 13.8% over the past 30 days, indicating a year-over-year decline of 18.84%. The consensus mark for second-quarter 2025 revenues is pegged at $7.41 billion, indicating year-over-year growth of 27%. Conclusion: Hold AMD Stock for Now AMD's expanding portfolio, strategic acquisitions and rich partner base are expected to improve its top-line growth. However, its near-term prospects are dull due to macroeconomic uncertainties and stiff competition, particularly from NVIDIA in the cloud data center and AI chip markets. The growing demand for custom AI chips, offered by companies like Broadcom, is increasing concerns over market share. Stretched valuation also remains a concern. AMD currently has a Zacks Rank #3 (Hold), suggesting that it may be wise for investors to wait for a more favorable entry point to accumulate the stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Advanced Micro Devices, Inc. (AMD): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Oracle Corporation (ORCL): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis Report This article originally published on Zacks Investment Research (
CTV News
13 hours ago
- CTV News
Ford struggles with supply of rare earth magnets
In this Feb. 11, 2016, file photo, the Ford logo on the grill of is displayed at the Pittsburgh International Auto Show in Pittsburgh. (AP Photo/Gene J. Puskar) Ford Motor Co is struggling with supplies of rare earth magnets, the automaker's CEO Jim Farley told Bloomberg News in an interview on Friday. China, which controls more than 90 per cent of global rare earth processing capacity, imposed new export licensing rules in April, tightening supply to Western manufacturers of everything from cars and fighter jets to household appliances. Automakers, especially those focused on EVs, are among the largest industrial consumers of rare earth materials. China granted temporary export licenses to rare-earth suppliers of the top three U.S. automakers, including Ford, earlier this month, according to a Reuters report. But Farley told Bloomberg News the company continues to struggle. 'It's day to day,' Farley said. 'We have had to shut down factories. It's hand-to-mouth right now.' Ford did not immediately respond to Reuters' request for a comment. The company had previously shut down production of its Explorer SUV at its Chicago plant for a week in May because of a rare-earth shortage. Shares of Ford were down close to one per cent in morning trade. They have risen more than seven per cent since the start of the year. Western countries have been trying to reduce reliance on Chinese rare earths by investing in alternative sources and refining capacity in places like Australia, Canada, and the United States. (Reporting by Abhinav Parmar and Nathan Gomes in Bengaluru; Editing by Leroy Leo)
